Skip to main content

Table 4 Allowed escape medication

From: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

Scalp/palms/soles

Low or high potency corticosteroids, calcitriol/calcipotriol, or a combination

Face and body

Low potency corticosteroids, calcitriol/calcipotriol, or topical tacrolimus 0.1% or 0.03%

inverse psoriasis

Topical tacrolimus 0.1% or 0.03%

Back to article page

Trials

ISSN: 1745-6215